Caprolactam Chem

  • Market Cap: Micro Cap
  • Industry: Commodity Chemicals
  • ISIN: INE470N01010
  • NSEID:
  • BSEID: 507486
INR
61.00
-2.24 (-3.54%)
BSENSE

Dec 05

BSE+NSE Vol: 302

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

302 (-90.68%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

54.05%

What does Caprolactam Chem do?

06-Jun-2025

Caprolactam Chemicals Ltd is a micro-cap company in the commodity chemicals industry, incorporated in 1988, with net sales of 2 Cr and a market cap of Rs 20 Cr as of March 2025. The company has faced financial challenges, reporting no net profit and a negative return on equity of -13.35%.

Overview:<BR>Caprolactam Chemicals Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in November 1988 and was registered as a sick company by the Board of Industrial and Finance Reconstruction (BIFR) in 2001. As of the latest quarter reported, which is March 2025, the company has net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 13 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.33 <BR>Return on Equity: -13.35% <BR>Price to Book: 3.67<BR><BR>Contact Details:<BR>Address: B/31 MIDC Industrial Area, Taluka - Mahad Raigad Maharashtra : 402302 <BR>Tel: 91-2145-233427 <BR>Email: caprolactumcl@gmail.com <BR>Website: http://www.caprolactam.co.in

Read More

Who are in the management team of Caprolactam Chem?

06-Jun-2025

As of March 2022, the management team of Caprolactam Chem includes Z S Bhanushali (Chairperson & Managing Director), S S Bhanushali (Whole Time Director & CFO), V P Adagale, R P Mange, and Poonam Bhavin Bhanushali (all Independent Directors), along with Dolly Dipesh Shah (Company Secretary & Compliance Officer).

As of March 2022, the management team of Caprolactam Chem includes the following individuals:<BR><BR>1. Z S Bhanushali - Chairperson & Managing Director<BR>2. S S Bhanushali - Whole Time Director & Chief Financial Officer<BR>3. V P Adagale - Independent Director<BR>4. R P Mange - Independent Director<BR>5. Poonam Bhavin Bhanushali - Independent Director<BR>6. Dolly Dipesh Shah - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Read More

Has Caprolactam Chem declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Caprolactam Chem?

03-Jun-2025

Caprolactam Chem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries. In terms of returns, India Glycols leads with 150.46% over one year, while Caprolactam Chem has the lowest at -33.11%.

Peers: The peers of Caprolactam Chem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals, India Glycols, Emmessar Biotech, and Link Pharma Chem, while Below Average management risk is noted for Fischer Medical, Caprolactam Chem, Vivid Global, and Kuwer Industries. Growth ratings show that Excellent capital structure is at GHCL, while Average capital structure is found at Tata Chemicals and the rest. Below Average capital structure is noted for Chemplast Sanmar, India Glycols, Fischer Medical, Caprolactam Chem, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.46%, while Caprolactam Chem has the lowest at -33.11%. Caprolactam Chem's return is significantly lower than all peers. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Caprolactam Chem, Emmessar Biotech, and Vivid Global.

Read More

What is the technical trend for Caprolactam Chem?

09-Jun-2025

As of June 6, 2025, Caprolactam Chem's technical trend is mildly bearish, supported by bearish MACD and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 6 June 2025, the technical trend for Caprolactam Chem has changed from bearish to mildly bearish. The weekly MACD remains bearish, and the monthly MACD is also bearish, indicating ongoing downward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly chart, but the monthly remains bearish, indicating mixed signals. Dow Theory indicates a mildly bearish stance on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages.

Read More

Who are the top shareholders of the Caprolactam Chem?

17-Jul-2025

The top shareholders of Caprolactam Chem include Siddharth Shankarlal Bhanushali with 22.98%, and individual investors who hold 43.84% of the shares. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Caprolactam Chem primarily consist of its promoters, with Siddharth Shankarlal Bhanushali holding the largest share at 22.98%. Additionally, individual investors collectively hold 43.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Read More

How big is Caprolactam Chem?

24-Jul-2025

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr and reported Net Sales of 6.73 Cr with a Net Profit loss of 0.71 Cr in the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 6.73 Cr. However, it experienced a Net Profit loss of 0.71 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

Read More

When is the next results date for Caprolactam Chem?

07-Aug-2025

Caprolactam Chem will announce its results on 14 August 2025.

Caprolactam Chem will declare its results on 14 August 2025.

Read More

Are Caprolactam Chem latest results good or bad?

15-Aug-2025

Caprolactam Chemicals' latest results show strong year-on-year sales growth of 59.51% and record profits, but declining liquidity and slower debt collection present challenges, indicating a mixed performance overall.

Caprolactam Chemicals has shown a mixed performance in its latest results for the quarter ending June 2025. On the positive side, the company reported a significant year-on-year growth in net sales of 59.51%, reaching Rs 6.46 crore for the nine-month period. Additionally, both profit before tax and profit after tax reached their highest levels in the last five quarters, with earnings per share increasing to Rs 0.78.<BR><BR>However, there are notable challenges as well. The company's cash and cash equivalents have decreased to Rs 0.08 crore, indicating a decline in short-term liquidity. Furthermore, the debtors turnover ratio has dropped to 2.39 times, suggesting a slowdown in the collection of debts.<BR><BR>Overall, while the growth in sales and profits is encouraging, the liquidity issues and slower debt collection raise concerns. Thus, the results can be seen as a mix of good and bad, highlighting both progress and challenges for Caprolactam Chemicals.

Read More

How has been the historical performance of Caprolactam Chem?

14-Nov-2025

Caprolactam Chem has experienced significant declines in net sales and profitability, with net sales dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025, and profit after tax turning negative at -0.71 Cr. The company faces ongoing financial difficulties, reflected in increased liabilities and stagnant cash flow.

Answer:<BR>The historical performance of Caprolactam Chem has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Caprolactam Chem's net sales peaked at 9.84 Cr in March 2023 but have since declined to 6.74 Cr by March 2025. The total operating income followed a similar trend, dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025. The company faced challenges with operating profit, which reached a high of 4.67 Cr in March 2023 but fell to 1.54 Cr by March 2025. Profit before tax also turned negative in March 2025 at -0.68 Cr, contrasting with a profit of 2.97 Cr in March 2023. Consequently, profit after tax reflected a loss of -0.71 Cr in March 2025, down from a profit of 2.55 Cr in March 2023. The company's total liabilities increased from 11.52 Cr in March 2023 to 14.28 Cr in March 2025, while total assets rose slightly from 11.52 Cr to 14.28 Cr in the same period. Cash flow from operating activities remained stagnant, with no cash inflow reported in March 2025, indicating ongoing financial difficulties. Overall, Caprolactam Chem has experienced a decline in sales and profitability, leading to a challenging financial position in recent years.

Read More

Should I buy, sell or hold Caprolactam Chem?

16-Nov-2025

Is Caprolactam Chem overvalued or undervalued?

29-Nov-2025

As of November 28, 2025, Caprolactam Chem is considered overvalued with a high PE ratio of 2771.50 and other metrics significantly above industry norms, making it a less prudent investment despite a recent 20.14% stock return.

As of 28 November 2025, the valuation grade for Caprolactam Chem has moved from fair to expensive, indicating a shift in perceived value. The company is currently overvalued based on its high PE ratio of 2771.50, a price to book value of 5.21, and an EV to EBITDA of 15.28, which are significantly higher than industry norms. <BR><BR>In comparison, peers such as Sun Pharma have a PE ratio of 38.03 and an EV to EBITDA of 25.17, while Cipla, which is considered attractive, has a PE ratio of 22.71 and an EV to EBITDA of 16.07. The stark contrast in these ratios suggests that Caprolactam Chem is not only overvalued relative to its peers but also lacks the financial performance metrics that would justify such a high valuation. Despite recent strong stock performance, with a one-year return of 20.14% compared to the Sensex's 8.43%, the underlying valuation metrics indicate that the stock is not a prudent investment at its current price.

Read More

Why is Caprolactam Chem falling/rising?

04-Dec-2025

As of 04-Dec, Caprolactam Chemicals Ltd's stock price is at Rs. 63.22, down 4.93% after a reversal from 11 days of gains. The stock has underperformed its sector and experienced a drop in investor participation, indicating negative overall sentiment.

As of 04-Dec, Caprolactam Chemicals Ltd's stock price is falling, currently at Rs. 63.22, which reflects a decrease of Rs. 3.28 or 4.93%. This decline follows a trend reversal after 11 consecutive days of gains. Although the stock opened with a gain of 3.76% and reached a new 52-week high of Rs. 69 earlier in the day, it subsequently fell to an intraday low of Rs. 63.18. <BR><BR>The stock has underperformed its sector by 5.22% today, indicating that it is not keeping pace with broader market trends. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 15.47% compared to the 5-day average. Despite trading above various moving averages, the overall sentiment appears to be negative, contributing to the stock's current decline.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.92%

  • Poor long term growth as Net Sales has grown by an annual rate of 11.23% and Operating profit at 5.06% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.86
2

Flat results in Sep 25

3

With ROCE of 5.7, it has a Expensive valuation with a 2.7 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Commodity Chemicals

stock-summary
Market cap

INR 29 Cr (Micro Cap)

stock-summary
P/E

2,908.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.68

stock-summary
Return on Equity

0.19%

stock-summary
Price to Book

5.47

Revenue and Profits:
Net Sales:
2 Cr
(Quarterly Results - Sep 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.96%
0%
27.96%
6 Months
51.06%
0%
51.06%
1 Year
16.63%
0%
16.63%
2 Years
10.59%
0%
10.59%
3 Years
15.75%
0%
15.75%
4 Years
-1.21%
0%
-1.21%
5 Years
255.69%
0%
255.69%

Caprolactam Chem for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
Announcements stock-summary

Disclosures Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011

01-Dec-2025 | Source : BSE

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011

Submission Of Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015 Form C

01-Dec-2025 | Source : BSE

Submission of Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations 2015 Form C

Submission Of Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015 Form C

01-Dec-2025 | Source : BSE

Submission of Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations 2015 Form C

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.23%
EBIT Growth (5y)
5.06%
EBIT to Interest (avg)
0.86
Debt to EBITDA (avg)
2.13
Net Debt to Equity (avg)
1.68
Sales to Capital Employed (avg)
0.65
Tax Ratio
92.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
8.43%
Valuation key factors
Factor
Value
P/E Ratio
2908
Industry P/E
34
Price to Book Value
5.47
EV to EBIT
38.04
EV to EBITDA
15.85
EV to Capital Employed
2.66
EV to Sales
4.31
PEG Ratio
28.04
Dividend Yield
NA
ROCE (Latest)
5.74%
ROE (Latest)
0.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Siddharth Shankarlal Bhanushali (22.98%)

Highest Public shareholder

None

Individual Investors Holdings

43.78%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -7.81% vs 59.01% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -63.89% vs 180.00% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.36",
          "val2": "2.56",
          "chgp": "-7.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.66",
          "val2": "1.04",
          "chgp": "-36.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.19",
          "val2": "0.18",
          "chgp": "5.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.13",
          "val2": "0.36",
          "chgp": "-63.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.97%",
          "val2": "40.63%",
          "chgp": "-12.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 73.59% vs -29.53% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 313.04% vs -195.83% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.93",
          "val2": "2.84",
          "chgp": "73.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.71",
          "val2": "0.82",
          "chgp": "108.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.37",
          "val2": "0.28",
          "chgp": "32.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.49",
          "val2": "-0.23",
          "chgp": "313.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.69%",
          "val2": "28.87%",
          "chgp": "5.82%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -7.07% vs -27.56% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -425.00% vs -96.65% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.13",
          "val2": "5.52",
          "chgp": "-7.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.29",
          "val2": "1.50",
          "chgp": "-14.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "0.37",
          "chgp": "21.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.26",
          "val2": "0.08",
          "chgp": "-425.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "25.15%",
          "val2": "27.17%",
          "chgp": "-2.02%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -3.16% vs -29.27% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -455.00% vs -92.16% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.74",
          "val2": "6.96",
          "chgp": "-3.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.53",
          "val2": "2.17",
          "chgp": "-29.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.63",
          "val2": "0.50",
          "chgp": "26.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.71",
          "val2": "0.20",
          "chgp": "-455.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.70%",
          "val2": "31.18%",
          "chgp": "-8.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
2.36
2.56
-7.81%
Operating Profit (PBDIT) excl Other Income
0.66
1.04
-36.54%
Interest
0.19
0.18
5.56%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.13
0.36
-63.89%
Operating Profit Margin (Excl OI)
27.97%
40.63%
-12.66%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is -7.81% vs 59.01% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is -63.89% vs 180.00% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
4.93
2.84
73.59%
Operating Profit (PBDIT) excl Other Income
1.71
0.82
108.54%
Interest
0.37
0.28
32.14%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.49
-0.23
313.04%
Operating Profit Margin (Excl OI)
34.69%
28.87%
5.82%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 73.59% vs -29.53% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 313.04% vs -195.83% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5.13
5.52
-7.07%
Operating Profit (PBDIT) excl Other Income
1.29
1.50
-14.00%
Interest
0.45
0.37
21.62%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.26
0.08
-425.00%
Operating Profit Margin (Excl OI)
25.15%
27.17%
-2.02%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -7.07% vs -27.56% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -425.00% vs -96.65% in Dec 2023

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
6.74
6.96
-3.16%
Operating Profit (PBDIT) excl Other Income
1.53
2.17
-29.49%
Interest
0.63
0.50
26.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.71
0.20
-455.00%
Operating Profit Margin (Excl OI)
22.70%
31.18%
-8.48%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -3.16% vs -29.27% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -455.00% vs -92.16% in Mar 2024

stock-summaryCompany CV
About Caprolactam Chemicals Ltd stock-summary
stock-summary
Caprolactam Chemicals Ltd
Micro Cap
Commodity Chemicals
Caprolactam Chemicals Ltd was incorporated in November, 1988. The Company was registered as sick company by the Board of Industrial and Finance Reconstruction (BIFR) in year 2001. The net worth of the Company as per Balance Sheet of year ending 31. 12. 2006 has turned positive which has been considered by the (BIFR) bench and the Bench allowed the MA and therefore, the Company was deregistered from the purview of SICA/BIFR.
Company Coordinates stock-summary
Company Details
B/31 MIDC Industrial Area, Taluka - Mahad Raigad Maharashtra : 402302
stock-summary
Tel: 91-2145-233427
stock-summary
caprolactumcl@gmail.com
Registrar Details
Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai